<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924660</url>
  </required_header>
  <id_info>
    <org_study_id>210982</org_study_id>
    <nct_id>NCT04924660</nct_id>
  </id_info>
  <brief_title>Novel Experimental COVID-19 Therapies Affecting Host Response</brief_title>
  <acronym>NECTAR</acronym>
  <official_title>CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of the Master Protocol is to find effective strategies for inpatient&#xD;
      management of patients with COVID-19. Therapeutic goals for patients hospitalized for&#xD;
      COVID-19 include hastening recovery and preventing progression to critical illness,&#xD;
      multiorgan failure, or death. Our objective is to determine whether modulating the host&#xD;
      tissue response improves clinical outcomes among patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus&#xD;
      disease 2019 (COVID-19), has resulted in a global pandemic. The clinical spectrum of COVID-19&#xD;
      infection is broad, encompassing asymptomatic infection, mild upper respiratory tract&#xD;
      illness, and severe viral pneumonia with respiratory failure and death. Between 13 and 40% of&#xD;
      patients become hospitalized, up to 30% of those hospitalized require admission for intensive&#xD;
      care, and there is a 13% inpatient mortality rate. The reasons for hospitalization include&#xD;
      respiratory support, as well as support for failure of other organs, including the heart and&#xD;
      kidneys. The risk of thrombotic complications is increased, even when compared to other viral&#xD;
      respiratory illnesses, such as influenza. While 82% of hospitalized patients with COVID-19&#xD;
      are ultimately discharged alive, median length of stay is 10-13 days.&#xD;
&#xD;
      Early work in treating COVID-19 has focused on preventing worsening of the initial clinical&#xD;
      presentation to prevent hospitalization and disease progression to organ failure and death.&#xD;
      Studies conducted under this Master Host Tissue Protocol are expected to extend our knowledge&#xD;
      of how to manage patients who are hospitalized for COVID-19 illness. Our objective is to&#xD;
      determine whether modulating the host tissue response improves clinical outcomes among&#xD;
      patients with COVID-19. This Master Protocol is a randomized, placebo-controlled trial of&#xD;
      agents targeting the host response in COVID-19 in hospitalized patients with hypoxemia. The&#xD;
      Master Host Tissue Protocol is designed to be flexible in the number of study arms, the use&#xD;
      of a single placebo group, and the stopping and adding of new therapies. Our primary outcome&#xD;
      is oxygen free days through day 28. This is defined as days alive and without supplemental&#xD;
      oxygen use during the first 28 days following randomization. Patients who die on or before&#xD;
      day 28 are assigned -1 oxygen free days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly allocated in a two-step process: 1) The participant will first be randomized in an m:1 ratio to receive an active study drug or placebo, where m represents the number of study drug arms for which the participant is eligible. 2) The participant will then be randomly assigned with equal probability to one of the study drug arms. Participants will receive the corresponding study drug or matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Which study drug arm the participant enters will be known to the research sites and the participants, but assignment to active versus placebo will be blinded. The randomized assignment, concealed from the research team, will be transmitted to the site pharmacy, who will provide study medication. The participant, treating clinicians, study personnel (other than the unblinded statistician who will prepare closed DSMB interim reports), and outcome assessors will all remain blinded to group assignment until after the database is locked and blinded analysis is completed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen free days through day 28.</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>This is defined as days alive and without supplemental oxygen use during the first 28 days following randomization. Patients who die on or before day 28 are assigned -1 oxygen free days. Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Day 1 to hospital discharge or Day 90 whichever comes first</time_frame>
    <description>Proportion of patients who die during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and oxygen free at Day 14</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>Proportion of patients oxygen free at day 14. Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and oxygen free at Day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Proportion of patients oxygen free at day 28. Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and free of new invasive mechanical ventilation at day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Proportion of patients alive free of new invasive mechanical ventilation at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Proportion of patients alive at Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60-day mortality</measure>
    <time_frame>Day 60</time_frame>
    <description>Proportion of patients alive at Day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>Proportion of patients alive at Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status assessed using World Health Organization (WHO) 8-point ordinal scale at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Ambulatory - Not hospitalized and no limitation of activities&#xD;
Ambulatory - Not hospitalized with limitation of activities or home oxygen use&#xD;
Hospitalized Mild Disease - Hospitalized, no oxygen therapy&#xD;
Hospitalized Mild Disease - Hospitalized, oxygen by mask or nasal prongs&#xD;
Hospitalized Severe Disease - Non-invasive ventilation or high-flow nasal cannula&#xD;
Hospitalized Severe Disease -Invasive mechanical ventilation&#xD;
Hospitalized Severe Disease - Invasive mechanical ventilation plus additional organ support with- vasopressors, RRT, or ECMO&#xD;
Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status assessed using WHO 8-point ordinal scale at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Ambulatory - Not hospitalized and no limitation of activities&#xD;
Ambulatory - Not hospitalized with limitation of activities or home oxygen use&#xD;
Hospitalized Mild Disease - Hospitalized, no oxygen therapy&#xD;
Hospitalized Mild Disease - Hospitalized, oxygen by mask or nasal prongs&#xD;
Hospitalized Severe Disease - Non-invasive ventilation or high-flow nasal cannula&#xD;
Hospitalized Severe Disease -Invasive mechanical ventilation&#xD;
Hospitalized Severe Disease - Invasive mechanical ventilation plus additional organ support with- vasopressors, RRT, or ECMO&#xD;
Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status assessed using WHO 8-point ordinal scale at Day 60</measure>
    <time_frame>Day 60</time_frame>
    <description>Ambulatory - Not hospitalized and no limitation of activities&#xD;
Ambulatory - Not hospitalized with limitation of activities or home oxygen use&#xD;
Hospitalized Mild Disease - Hospitalized, no oxygen therapy&#xD;
Hospitalized Mild Disease - Hospitalized, oxygen by mask or nasal prongs&#xD;
Hospitalized Severe Disease - Non-invasive ventilation or high-flow nasal cannula&#xD;
Hospitalized Severe Disease -Invasive mechanical ventilation&#xD;
Hospitalized Severe Disease - Invasive mechanical ventilation plus additional organ support with- vasopressors, RRT, or ECMO&#xD;
Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days through day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Days alive and not hospitalized during the first 28 days following randomization. Patients who die on or before day 28 are assigned a value -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days through day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Days alive and not receiving mechanical ventilation during the first 28 days following randomization. Patients who die on or before day 28 are assigned a value -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory failure-free days through day 28</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Days alive and not in respiratory failure during the first 28 days following randomization. A respiratory failure-free day is defined as a day alive without the use of HFNC, NIV, IMV, or (ECMO). Patients who die on or before day 28 are assigned a value -1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Renal outcomes: acute kidney Injury</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with evidence of acute kidney injury using the KDIGO Stage 2 criteria for serum creatinine relative to baseline at Day 0.</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial injury</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with Myocardial injury described by changes in troponin before, during and after therapy during hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>RAAS pathway mechanistic biomarkers</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with changes in RAAS mechanistic biomarkers (AngII, Ang(1-7), ACE activity and ACE2 activity) before, during and after therapy during hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Trajectories of biomarkers related to COVID-19</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with changes in trajectories of biomarkers related to COVID-19</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in NT-proBNP (pending funding)</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with changes in NTproBNP before, during and after therapy during hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypotension</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with hypotension defined by low arterial blood pressure leading to either [1] initiation or increase in vasopressor therapy, [2] administration of a fluid bolus of 500 ml or more, or [3] modification of the dose or discontinuation of the study drug.</description>
  </other_outcome>
  <other_outcome>
    <measure>Allergic reaction</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants with allergic reaction, including rash and angioedema</description>
  </other_outcome>
  <other_outcome>
    <measure>Incident renal replacement therapy during hospitalization</measure>
    <time_frame>Day 0 to Day 5 or hospital discharge whichever comes first</time_frame>
    <description>Proportion of participants requiring renal replacement therapy</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>TXA127</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An investigational peptide agonist of Mas receptors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An investigational peptide biased agonist of the AT1 receptor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% infused to match the duration of the agent for TXA127, TRV027, and APN01.&#xD;
Orange film-coated, plain, bioconvex tablets for fostamatinib.&#xD;
For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An investigational oral spleen tyrosine kinase inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APN01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An investigational, recombinant, human, soluble angiotensin-converting enzyme 2 (rhsACE2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TXA127</intervention_name>
    <description>TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.</description>
    <arm_group_label>TXA127</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV027</intervention_name>
    <description>TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.</description>
    <arm_group_label>TRV027</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.&#xD;
Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.</description>
    <arm_group_label>Fostamatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APN01</intervention_name>
    <description>APN01 0.4 mg/kg will be infused twice daily, every 12 hours, over a 30-minute period for the earlier of 5 days or hospital discharge.</description>
    <arm_group_label>APN01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Hospitalized for COVID-19&#xD;
&#xD;
          2. ≥18 years of age&#xD;
&#xD;
          3. SARS-CoV-2 infection, documented by:&#xD;
&#xD;
               1. a nucleic acid test (NAT) or equivalent testing within 3 days prior to&#xD;
                  randomization OR&#xD;
&#xD;
               2. documented by NAT or equivalent testing more than 3 days prior to randomization&#xD;
                  AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the&#xD;
                  responsible investigator (For non-NAT tests, only those deemed with equivalent&#xD;
                  specificity to NAT by the protocol team will be allowed. A central list of&#xD;
                  allowed non- NAT tests is maintained in in the study protocol)&#xD;
&#xD;
          4. Hypoxemia, defined as SpO2 &lt;92% on room air, new receipt of supplemental oxygen to&#xD;
             maintain SpO2 ≥92%, or increased supplemental oxygen to maintain SpO2 ≥92% for a&#xD;
             patient on chronic oxygen therapy&#xD;
&#xD;
          5. Symptoms or signs of acute COVID-19, defined as one or more of the following:&#xD;
&#xD;
               1. cough&#xD;
&#xD;
               2. reported or documented body temperature of 100.4 degrees Fahrenheit or greater&#xD;
&#xD;
               3. shortness of breath&#xD;
&#xD;
               4. chest pain&#xD;
&#xD;
               5. infiltrates on chest imaging (x-ray, CT scan, lung ultrasound)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. History of sensitivity (including angioedema) or allergic reaction to medication&#xD;
             targeting the RAAS system including study medications or other allergy in the opinion&#xD;
             of the investigator that contraindicates participation&#xD;
&#xD;
          2. COVID-19 symptom onset &gt;14 days prior to randomization&#xD;
&#xD;
          3. Hospitalized for &gt;72 hours prior to randomization&#xD;
&#xD;
          4. Hemodynamic instability - defined as MAP &lt; 65 mmHg at time of randomization confirmed&#xD;
             on two measurements 5 minutes apart OR vasopressors at or above norepinephrine&#xD;
             equivalent of 0.1 mcg/kg/min in prior 4 hours to maintain MAP &gt; 65 mmHg&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Breastfeeding&#xD;
&#xD;
          7. Prisoners&#xD;
&#xD;
          8. End-stage renal disease (ESRD) on dialysis&#xD;
&#xD;
          9. Patient and/or clinical team is not pursuing full medical management (if a patient has&#xD;
             a Do Not Resuscitate order that precludes chest compressions in the event of a cardiac&#xD;
             arrest but is otherwise pursuing full medical management, he/she is eligible for this&#xD;
             trial).&#xD;
&#xD;
         10. Known severe renal artery stenosis&#xD;
&#xD;
         11. Known significant left ventricular outflow obstruction, such as obstructive&#xD;
             hypertrophic cardiomyopathy or severe aortic or mitral stenosis&#xD;
&#xD;
         12. Randomized in another trial evaluating RAAS modulation in the prior 30 days&#xD;
&#xD;
         13. The treating clinician expects inability to participate in study procedures or&#xD;
             participation would not be in the best interests of the patient&#xD;
&#xD;
        The following exclusion criteria differ from the master protocol criteria:&#xD;
&#xD;
        TXA127-specific exclusion criteria:&#xD;
&#xD;
        • Patient unable to participate or declines participation in the TXA127/Ang(1-7) arm.&#xD;
&#xD;
        TRV027-specific exclusion criteria:&#xD;
&#xD;
          -  Participants on ARBs will be excluded from this study arm.&#xD;
&#xD;
          -  Patient unable to participate or declines participation in the TRV027 arm.&#xD;
&#xD;
        Fostamatinib specific exclusion criteria:&#xD;
&#xD;
          -  AST or ALT ≥ 5 × upper limit of normal (ULN) or ALT or AST ≥ 3 × ULN and total&#xD;
             bilirubin ≥ 2 × ULN&#xD;
&#xD;
          -  SBP &gt; 160 mmHg or DBP &gt; 100 mmHg at the time of screening and randomization&#xD;
&#xD;
          -  ANC &lt; 1000/mL&#xD;
&#xD;
          -  Patient requires use of strong CYP3A modulators from Table above (Clarithromycin,&#xD;
             Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Ritonavir, Saquinavir,&#xD;
             Telithromycin, Troleandomycin, Carbamazepine, Efavirenz, Enzalutamide, Modafinil,&#xD;
             Nevirapine, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, St. John's&#xD;
             Wort, or Troglitazone).&#xD;
&#xD;
          -  Patient unable to participate or declines participation in the fostamatinib arm.&#xD;
&#xD;
        APN01 specific exclusion criteria:&#xD;
&#xD;
        • Patient unable to participate or declines participation in the APN01 arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean P. Collins, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri L. Dixon, B.S.N., R.N.</last_name>
    <phone>615-343-0266</phone>
    <email>sheri.dixon@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sean P. Collins, M.D.</last_name>
    <phone>615-875-6151</phone>
    <email>sean.collins@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chandler Regional Medical Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Tiffany, MD, PHD</last_name>
      <phone>480-728-4427</phone>
      <email>brian.tiffany@dignityhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Tanner</last_name>
      <phone>480 728 4427</phone>
      <email>charlotte.tanner@dignityhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Chen, MD</last_name>
      <phone>310-423-1158</phone>
      <email>peter.chen@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Tabia Richardson</last_name>
      <phone>424 315 2861</phone>
      <email>tabia.richardson@cshs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph E Levitt, MD, MS</last_name>
      <phone>650-723-7409</phone>
      <email>jlevitt@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rosemary Vojnik</last_name>
      <phone>650-725-1941</phone>
      <email>rvojnik@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adit Ginde, MD, MPH</last_name>
      <phone>720-848-6777</phone>
      <email>adit.ginde@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivor S Douglas, MD</last_name>
      <phone>303-602-5012</phone>
      <email>ivor.douglas@dhha.org</email>
    </contact>
    <contact_backup>
      <last_name>Terra D Hiller, MSN</last_name>
      <phone>303-602-1438</phone>
      <email>terra.hiller@dhha.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ivor S Douglas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basmah Safdar, MD</last_name>
      <phone>203-737-6152</phone>
      <email>basmah.safdar@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Malicki</last_name>
      <phone>480 728 4427</phone>
      <email>caitlin.malicki@yale.du</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Merck, MD, MPH</last_name>
      <phone>352-265-5911</phone>
      <email>lmerck@ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Meenakshi Balakrishnan</last_name>
      <phone>919-949-5536</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ponce de Leon Clinical Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valeria D Cantos Lucio, MD</last_name>
      <phone>470-603-5784</phone>
      <email>valeria.d.cantos.lucio@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natascha R Cook</last_name>
      <phone>404 251 8717</phone>
      <email>ncook@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John G Quigley, MD</last_name>
      <phone>312-355-0784</phone>
      <email>seanq@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Keri S Kim</last_name>
      <phone>312 413 1300</phone>
      <email>skim42@uic.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neeraj Desai, MD</last_name>
      <phone>847-230-3537</phone>
      <email>neeraj.desai@amitahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Dohe</last_name>
      <phone>847 230 3537</phone>
      <email>carrie.dohe@amitahealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Thomas, MD</last_name>
      <phone>225-765-7979</phone>
      <email>christopher.thomas@fmolhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Jill Tomkins</last_name>
      <phone>225 381 2755</phone>
      <email>jill.tomkins@fmolhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Vonderhaar, MD</last_name>
      <phone>504-842-1618</phone>
      <email>derek.vonderhaar@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Hailey Anderson</last_name>
      <phone>504-842-1618</phone>
      <email>hailey.anderson@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Derek Vonderhaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David N Hager, MD, PHD</last_name>
      <email>dhager1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David N Hager, MD, PHD</last_name>
      <phone>443-287-4715</phone>
      <email>dhager1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Harith H Ali</last_name>
      <phone>410 614 6292</phone>
      <email>hali20@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine L Boyle, MD</last_name>
      <phone>617-754-2287</phone>
      <email>klboyle@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Hayes</last_name>
      <phone>617 754 2287</phone>
      <email>srhayes@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter C Hou, MD</last_name>
      <phone>617-732-5638</phone>
      <email>phou@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Steven Miyawaki</last_name>
      <phone>617 732 5638</phone>
      <email>smiyawaki@bwh.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Schrager, MD</last_name>
      <phone>617-831-7671</phone>
      <email>hschrager@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Dwyer</last_name>
      <phone>617-243-6597</phone>
      <email>mkdwyer@partners.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert C Hyzy, MD</last_name>
      <phone>734-232-4285</phone>
      <email>rhyzy@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristine Nelson</last_name>
      <phone>734 936 5201</phone>
      <email>flygrrl@med.umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A Puskarich, MD, MS</last_name>
      <phone>612-873-9528</phone>
      <email>Michael.puskarich@hcmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Audrey F Hendrickson</last_name>
      <phone>612-873-3284</phone>
      <email>audrey.henrickson@hcmed.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Puskarich, MD</last_name>
      <phone>612-625-2531</phone>
      <email>mike-em@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Staloch</last_name>
      <phone>612 626 6911</phone>
      <email>staloch@umn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan E Jones, MD</last_name>
      <phone>601-815-3008</phone>
      <email>aejones@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebekah K Peacock</last_name>
      <phone>601-984-4103</phone>
      <email>rpeacock@umc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Javaheri, MD</last_name>
      <phone>314-747-2246</phone>
      <email>ali.javaheri@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Stilinovic</last_name>
      <phone>314-272-8367</phone>
      <email>sstilinovic@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron N Barksdale, MD</last_name>
      <phone>402-599-5237</phone>
      <email>aaron.barksdale@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brooklin K Zimmerman</last_name>
      <phone>402 559 5237</phone>
      <email>brooklin.zimmerman@unmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle S Harkins, MD</last_name>
      <phone>505-272-4751</phone>
      <email>mharkins@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Brito</last_name>
      <phone>505-272-9542</phone>
      <email>rbrito@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle S Harkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Weiler Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle N Gong, MD, MS</last_name>
      <phone>718-904-3979</phone>
      <email>mgong@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Lopez</last_name>
      <phone>718-920-2956</phone>
      <email>brenda.lopez@einsteinmed.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle N Gong, MD, MS</last_name>
      <phone>718-920-2956</phone>
      <email>mgong@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Ceusters</last_name>
      <phone>718-920-2956</phone>
      <email>dceuster@montefiore.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanine M D'Armiento, MD, PhD</last_name>
      <phone>212-305-3745</phone>
      <email>jmd12@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura D Fonseca</last_name>
      <phone>212 305 3745</phone>
      <email>lf2560@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Subhashini Sellers, MD</last_name>
      <email>sasellers@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nayeem Choudhury</last_name>
      <email>nayeem_choudhury@med.unc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clark Files, MD</last_name>
      <phone>410-530-5719</phone>
      <email>clark.files@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lori Flores, DNP</last_name>
      <phone>336-713-0008</phone>
      <email>lflores@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Clark Files, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Akron General</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lokesh K Venkateshaiah, MD</last_name>
      <phone>330-344-1570</phone>
      <email>VenkatL@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Debra K Hudock</last_name>
      <phone>330-344-6676</phone>
      <email>HudockD@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin M Hudock, MD, MSTR</last_name>
      <phone>513-558-7736</phone>
      <email>hudockkn@ucmail.uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kiersten M Rush</last_name>
      <phone>513 803 7819</phone>
      <email>rushkm@mail.uc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhijit Duggal, MD</last_name>
      <phone>216-444-4838</phone>
      <email>duggala2@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Bryan Poynter, BS</last_name>
      <phone>216-538-9571</phone>
      <email>poynteb@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Abhijit Duggal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akram Khan, MD</last_name>
      <phone>503-494-9443</phone>
      <email>khana@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel Mills</last_name>
      <phone>503 494 1620</phone>
      <email>millsem@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina T Gentile, MD</last_name>
      <phone>215-727-5483</phone>
      <email>nina.gentile@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Reimer</last_name>
      <phone>215 707 8402</phone>
      <email>hannah.reimer@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Baram, MD</last_name>
      <phone>215-955-5759</phone>
      <email>michael.baram@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maura Wasilewski</last_name>
      <phone>215 955 6591</phone>
      <email>maura.wasilewski@jefferson.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley H. Self, MD, MPH</last_name>
      <phone>615-936-8047</phone>
      <email>wesley.self@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Christina Kampe</last_name>
      <phone>615-936-4790</phone>
      <email>christina.kampe@vumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel M Courtney, MD</last_name>
      <phone>214-647-2767</phone>
      <email>daniel.coutney@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katherine R Martin</last_name>
      <phone>214 648 2767</phone>
      <email>riley.martin@UTSouthwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Lanspa, MD</last_name>
      <phone>435-730-1475</phone>
      <email>michael.lanspa@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Aston</last_name>
      <phone>801 507 4324</phone>
      <email>valerie.aston@imail.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Harris, MD</last_name>
      <phone>801-581-5811</phone>
      <email>estelle.harris@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Macy Barrios</last_name>
      <phone>801-581-5811</phone>
      <email>macy.barrios@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Estelle Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UVA Health</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery M Sturek, MD</last_name>
      <email>JMS3HK@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather M Haughey</last_name>
      <email>hmh8f@hscmail.mcc.virginia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VCU Health</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjolein de Wit, MD, MS</last_name>
      <phone>804-827-0721</phone>
      <email>marjolein.dewit@vcuhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Mason</last_name>
      <phone>804-827-0721</phone>
      <email>jessica.mason1@vcuhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas Johnson, MD</last_name>
      <email>nickj45@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Gundel</last_name>
      <phone>206 744 8468</phone>
      <email>sgundel@uw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Sean Collins</investigator_full_name>
    <investigator_title>Professor, Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19 drug treatment</keyword>
  <keyword>RAAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin I (1-7)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

